Data from the phase 1/2 Beacon trial indicated that Beam-101, the company’s sickle cell therapy, increased fetal hemoglobin levels from an initial range of 4% to 17% to levels of 72% to 74% within two months. Hemoglobin levels remained elevated for two patients at five- and six-month follow-ups.
One patient died four months after the Beam-101 infusion due to respiratory failure. The death was likely related to busulfan conditioning and was determined to be unrelated to the treatment itself.
No other grade 3 or higher adverse events or serious adverse events related to the treatment were reported.
Beam Therapeutics plans to expand the trial to a cohort of 42 participants.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
